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Running title: MYC in breast cancer subtypes 
Abstract 
Introduction 
MYC is amplified in approximately 15% of breast cancers (BC) and is associated with poor 
outcome. c-MYC protein is multi-faceted and participates in many aspects of cellular 
function and is linked with therapeutic response in BC. We hypothesised that the functional 
role of c-MYC differs between molecular subtypes of BC.   
Methods 
We therefore investigated the correlation between c-MYC protein expression and other 
proteins involved in different cellular functions together with clinicopathological parameters, 
patients’ outcome and treatments in a large early-stage molecularly characterised series of 
primary invasive BC (n=1,106) using immunuohistochemistry. The METABRIC BC cohort 
(n=1,980) was evaluated for MYC mRNA expression and a systems biology approach utilised 
to identify genes associated with MYC in the different BC molecular subtypes. 
Results 
High MYC and c-MYC expression was significantly associated with poor prognostic factors 
including grade and basal-like BC. In luminal A tumours, c-MYC was associated with ATM 
(p=0.005), Cyclin B1 (p=0.002), PIK3CA (p=0.009) and Ki67 (p<0.001). In contrast, in 
basal-like tumours, c-MYC showed positive association with Cyclin E (p=0.003) and p16 
(p=0.042) expression only. c-MYC was an independent predictor of a shorter distant 
metastases free survival in luminal A LN+ tumours treated with endocrine therapy (ET; 
p=0.013). In luminal tumours treated with ET, MYC mRNA expression was associated with 
BC specific survival (p=0.001). In ER positive tumours, MYC was associated with expression 
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of translational genes whilst in ER negative tumours it was associated with upregulation of 
glucose metabolism genes. 
Conclusions 
c-MYC function is associated with specific molecular subtypes of BC and its overexpression 
confers resistance to ET. The diverse mechanisms of c-MYC function in the different 
molecular classes of BC warrants further investigation particularly as potential therapeutic 
targets. 
Keywords 




In a meta-analysis of 3,797 patients, V-Myc Avian Myelocytomatosis Viral Oncogene 
Homolog (MYC) is amplified in 15.7% of breast cancers (BC) and is associated with higher 
tumour grade, advanced stage and Progesterone Receptor (PgR) negative tumours resulting in 
an association with poor overall survival and disease recurrence independent of existing 
prognostic factors(Deming et al., 2000).  The c-MYC protein is multi-faceted and participates 
in many aspects of cellular function, including replication, growth, metabolism, 
differentiation, and apoptosis(Liao and Dickson, 2000). The mechanisms of c-MYC action in 
controlling these different roles remain poorly understood. However, it may be context or 
isoform dependent whether c-MYC promotes cell proliferation or apoptosis(Deming et al., 
2000, Liao and Dickson, 2000, Patel et al., 2004). 
The expression of c-MYC is regulated by oestrogen via the Phosphatidylinositol-4,5-
Bisphosphate 3-Kinase (PI-3 Kinase) pathways, amongst other signalling pathways, 
promoting cell proliferation and survival(Liao et al., 2000). Anti-oestrogen treatment, 
including aromatase inhibitors, tamoxifen and faslodex, all downregulate MYC mRNA 
inducing cell cycle arrest(Carroll et al., 2002). There is also strong evidence that c-MYC 
plays a role in the development of anti-oestrogen resistance where it is frequently 
overexpressed during progression and distant relapse of Oestrogen Receptor (ER)-positive 
BC treated with adjuvant hormonal therapy(Planas-Silva et al., 2007). Clinical evidence also 
suggests that c-MYC and B-Cell CLL/Lymphoma 2 (Bcl-2) act in concert to promote lymph 
node metastasis in early BC(Sierra et al., 1999).  c-MYC overexpression can also cause DNA 
damage and subsequently trigger apoptosis via DNA damage response pathways. ATM 
Serine/Threonine Kinase (ATM); a critical DNA double strand break repair protein, is 
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upregulated in response to such DNA damage and is necessary for p53 activation and 
suppression of tumour development. 
In a recent study, it was demonstrated that c-MYC expression was up-regulated through the 
cross-talk between ER and Human Epidermal Growth Factor Receptor 2 (HER2) in BC 
cells(Chen et al., 2015). Cross-talk between ER and HER2 regulates c-MYC-mediated 
glutamine metabolism in aromatase inhibitor resistant BC cells.  
Therapeutic strategies aimed at targeting c-MYC have emerged, including interfering with c-
MYC synthesis, dimerisation, stability and transcriptional activity(Boddupally et al., 2012, 
Albihn et al., 2010, Dang, 2012, Vita and Henriksson, 2006). However, the effectiveness of 
targeting c-MYC using single agents, failure to achieve long-lasting efficacy is observed 
because MYC function controls expression of multiple genes and cancer cells can recover 
from oncogene addiction. 
Thus targets aimed at inhibiting downstream signalling pathways in c-MYC dependent 
tumours such as stress-response, metabolism and cell cycle pathways are currently the focus 
for new therapeutic opportunities(Dang, 2012). Several clinical trials focussed on these 
biological processes are currently underway(Horiuchi et al., 2014) 
In this study, we hypothesised that the functional role of c-MYC differs between molecular 
subtypes of BC and would influence the response for different type of adjuvant therapeutic 
regimens. We therefore investigated the correlation between MYC mRNA and c-MYC protein 
expression and other proteins involved in cell proliferation, DNA damage and apoptosis, in 
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addition to clinicopathological parameters, outcome and treatments in a large cohort of 
molecularly characterised early-stage invasive primary breast carcinoma.  
2. Materials and Methods  
2.1 MYC gene expression 
MYC gene expression was evaluated in a cohort of 1,980 breast cancer samples using the 
Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) cohort(Curtis 
et al., 2012). RNA from fresh frozen tumours were subject to transcriptional profiling using 
the Illumina HT-12 v3 platform and data was pre-processed and normalised as described 
previously(Curtis et al., 2012). In this cohort, patients with ER positive and/or lymph node 
negative tumours did not receive adjuvant chemotherapy, whilst those with ER negative and/
or lymph node positive tumours received adjuvant chemotherapy.                                            
2.2 c-MYC protein expression 
2.2.1 Study Patients 
Immunohistochemistry was conducted using a large cohort of patients comprising a well-
characterised consecutive series of early stage (TNM Stage I-III excluding T3 and T4 
tumours) sporadic primary operable invasive BC from patients (age ≤70 years) enrolled into 
the Nottingham Tenovus Primary Breast Carcinoma Series that presented at Nottingham City 
Hospital between 1989 and 1998 (n=1,106) and managed in accordance to a uniform 
protocol. Patients’ clinical history, tumour characteristics, information on therapy and 
outcomes are prospectively maintained. Outcome data was collected on a prospective basis 
and included development and time to distant metastasis (DM) and BC specific survival 
(BCSS). DM free survival is defined as the time (in months) from the date of primary surgery 
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to the appearance of DM. The BCSS is defined as the time (in months) from the date of 
primary surgery to the date of BC-related death. Luminal tumours were defined as ER+, 
Triple Negative status were all those tumours not expressing ER, PgR and HER2, and 
HER2+ status defined as all tumours overexpressing HER2 irrespective of ER status. Patients 
with Luminal tumours had the best BCSS followed by those with Triple Negative tumours 
(Supplementary Figure 1). Patients with HER2+ tumours had the poorest outcome. 
2.2.2 Validating antibody specificity 
The specificity of the anti-c-MYC primary antibody (Clone 9E100; Abcam Ltd, Cambridge, 
UK) was validated using Western blotting (WB). WB was performed on whole cell lysates of 
MDA-MB-468 human breast cancer cell line (obtained from the American Type Culture 
Collection; Rockville, MD, USA) using 1:500 dilution of the primary antibody dilution, and 
1:15000 horseradish peroxidase conjugated secondary antibody (SA) (Li-cor Biosciences, 
UK). 5% milk (Marvel Original Dried Skimmed Milk, Premier Food Groups Ltd., UK) was 
used for blocking. HRP conjugated Anti-Rabbit β-actin (Clone AC-15; Sigma, UK) at 1:5000 
was used as a house-keeping protein. A protein ladder (PageRuler Plus Prestained Protein 
Ladder, ThermoScientific, U.S.) was included. Chemiluminescence was used to visualise 
bands using Odyssey Fc (Li-cor Biosciences, USA) which showed a single specific band at 
the right size (41 KDa) for c-MYC protein, confirming the specificity of the antibody 
(Supplementary Figure 2A). 
2.2.3 Tissue arrays and Immunohistochemistry 
Tumour samples were arrayed as previously described(Abd El-Rehim et al., 2005). In brief, 
tissue cores with a diameter of 0.6 mm were punched from the representative tumour regions 
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of each donor block. Cores were precisely arrayed into a new recipient paraffin blocks using 
a tissue microarrayer (Beecher Instruments). Immunohistochemical staining was performed 
on 4 µm thick sections using Novolink polymer detection system (Leica Biosystems, 
RE7150-K), composed of Peroxidase Block, Post Primary Block, Novolink Polymer, 3,3'-
diaminobenzidine (DAB) chromogen and substrate buffer, and Novolink haematoxylin. 
Briefly, tissue slides were deparaffinised with xylene and rehydrated through 3 changes of 
alcohol. Heat-induced antigen epitope retrieval was performed in citrate buffer (pH 6.0) for 
20 minutes using a microwave oven. Endogenous peroxidase activity was blocked by 
Peroxidase Block for 5 minutes. Slides were washed with Tris-Buffered Saline (TBS, pH 
7.6), followed by application of Protein Block for 5 minutes. Following another TBS wash, 
mouse monoclonal primary antibody for c-MYC (Clone 9E100; Abcam Ltd, Cambridge, UK) 
at 1:100 in Leica antibody diluent (RE7133), was applied and incubated for 45 minutes. 
Slides were washed with TBS followed by incubation with Post Primary Block for 30 
minutes followed by a TBS wash. Novolink polymer was applied for 30 minutes. DAB 
working solution made up of 1:20 DAB chromogen in DAB substrate buffer was prepared 
and applied for 5 minutes. Slides were counterstained with Novolink haematoxylin for 6 
minutes, dehydrated and coverslipped. Negative (omission of the primary antibody) and 
positive controls were included according to manufacturer datasheet of each antibody.  
Immunhistochemical staining and dichotomisation of the other biomarkers included in this 
study were as per previous publications(Aleskandarany et al., 2012, Aleskandarany et al., 
2011, Aleskandarany et al., 2010b, Barros et al., 2014, Elsheikh et al., 2008, Habashy et al., 
2013, Rakha et al., 2009, Rakha et al., 2007, Aleskandarany et al., 2010a) (Supplementary 
Table 1)  
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2.2.4 Evaluation of Immunohistochemical Staining 
Assessment of staining was estimated subjectively on intensity corresponding to negative, 
weak, moderate and strong nuclear and/or cytoplasmic staining. Dichotomisation of c-MYC 
protein expression was based on the mean resulting in negative/weak (MYC negative) and 
moderate/strong (MYC positive) groups which were selected prior to analysis.  
2.3 Artificial neural network (ANN) model 
A nonlinear ANN modelling based approach was utilised to identify those gene probes 
associated with high MYC expression in ER positive and ER negative disease using the 
METABRIC cohort. A total of 48,803 probes were screened for each sample. The data 
mining algorithm comprised a three layer multilayer perception architecture modified with a 
feed forward back-propagation algorithm and a sigmoidal transfer function, as previously 
described(Lancashire et al., 2010, Abdel-Fatah et al., 2014). The network momentum and 
learning rate were respectively set as 0.1 and 0.5. A parsimonious structure using two hidden 
nodes and three split Monte Carlo Cross validation were utilised to prevent over fitting. The 
output node was coded as 0 if a case was low MYC expression (median) and as 1 if was 
above median expression value. Inputs were ranked in ascending order based on their average 
classification error for the test subset. The top 200 predictive genes identified were then 
applied to an ANN based network inference algorithm as described in earlier studies25,26. This 
model predicted a weighted link (direction and magnitude) between each of the top 200 gene 
probe markers associated with MYC expression and every other marker in the top 200. The 
100 strongest interactions based on the magnitude were then visualised as a map with Cyto-
scape(Smoot et al., 2011). 
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2.4 External validation cohorts: For external validation of MYC mRNA expression, 
bc-GenExMiner v3.0 (Breast Cancer Gene-Expression Miner v3.2) online dataset 
(http://bcgenex.centregauducheau.fr) was used. In this study, the Gene correlation 
targeted analysis offering the possibility to evaluate the correlation between MYC 
and candidate genes in ER+ and ER- breast cancer, was used (Jezequel et al., 
2012). 
2.5 Statistical analysis 
Statistical analysis was performed using SPSS 21.0 statistical software (SPSS Inc., Chicago, 
IL, USA). Univariate and multivariate analyses were performed by chi-squared test, Log rank 
and Cox regression analysis, respectively. Survival curves were analysed by the method of 
Kaplan-Meier (Kaplan and Meier, 1958). A p-value <0.01 was considered significant. This 
study complied with reporting recommendations for tumour marker prognostic studies 
(REMARK) criteria(McShane et al., 2005). Recursive partitioning (Hothorn et al., 2006) was 
used to identify a cut-off in gene expression values such that the resulting subgroups have 
significantly different survival courses. 
2.6 Ethics 
This study was approved by the Nottingham Research Ethics Committee 2 under the title 
‘Development of a molecular genetic classification of breast cancer’. 
3. Results 
3.1 MYC expression and clinicopathological parameters 
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High MYC mRNA expression was observed in 260/1,977 (13.1%) tumours. Positive 
cytoplasmic and nuclear expression of c-MYC protein was observed in 559/1,106 (50.5%) of 
invasive BC cases while 547 (49.5%) were negative, Supplementary Figure 2B-C.  
There was significant association between MYC mRNA and c-MYC protein expression with 
poor prognostic indicators of BC. High MYC mRNA expression was associated with high 
grade (p<0.001) and Nottingham Prognostic Index (p=0.001) but not size or lymph node 
stage (Table 1). Positive c-MYC protein expression was significantly associated with higher 
tumour grade (p=0.043), mitotic frequency scores (p=0.004), nuclear pleomporphism 
(p=0.012) and lymph node stage (p=0.046, Table 1). c-MYC was also significantly associated 
with histological tumour type where more expression was observed in medullary-like 
tumours (22/31, 71.0%) but was less likely to be expressed in lobular tumours (41/106, 
38.7%). However, there was no association between c-MYC with patient age, tumour size, 
tubule formation or lymphovascular invasion.  
3.2 MYC expression and biomarkers 
High MYC mRNA expression was significantly associated with ER and PgR negative 
tumours (both p<0.001), HER2 positive (p=0.001) as well as triple-negative tumours 
(p<0.001, Table 1). There was no association between c-MYC protein expression with either 
ER, PgR nor HER2 (Table 1). Positive c-MYC protein  expression was associated with 
markers of basal-like phenotype including cytokeratin 5/6 and Epidermal Growth Factor 
Receptor (EGFR; p=0.002 and 0.001, respectively, Table 2).  
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c-MYC expression was significantly expressed in breast tumours with high ATM and 
PI-3Kinase (both p=0.001, Table 2). Cell cycle regulators p16, Cyclin B1, and Cyclin E were 
also significantly expressed in breast tumours with positive expression of c-MYC (p=0.018, 
p=0.023 and p=0.001, respectively). Tumours with high c-MYC showed high expression of 
Ki67 (p<0.001). There was no association between c-MYC expression with BCL2, p53, p21, 
pAKTs473 or Retinoblastoma (Rb). 
3.3 MYC expression in molecular BC subtypes 
In terms of the intrinsic subtypes (PAM50), high MYC mRNA expression was significantly 
expressed in basal tumours (p<0.001) whereas low expression was associated with luminal A 
and HER2 tumours (both p<0.001). There was no association between MYC expression and 
luminal B tumours.  
Those biomarkers that were associated with high c-MYC expression in the unselected breast 
tumours were further investigated in the different BC molecular classes. This showed 
differential association between molecular classes.  In luminal A (ER+/HER2-) tumours, c-
MYC expression was significantly associated with ATM (p=0.005), Cyclin B1 (p=0.002), 
PIK3CA (p=0.009) and Ki67 (p<0.001) but not Cyclin E nor p16 (Table 2). In contrast, in 
basal-like tumours, c-MYC expression was associated with positive Cyclin E (p=0.003) and 
p16 (p=0.042) expression but not ATM, Cyclin B1, PI-3 Kinase or Ki67 (Table 2). In HER2+ 
tumours, positive c-MYC expression was associated with ATM (p=0.001) and Ki67 
(p=0.030) expression only. 
3.4 MYC expression and patients’ outcome 
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The high expression of MYC mRNA (p=0.007, Figure 1A) and c-MYC protein (p=0.001, 
Figure 1B) were both significantly associated with poor patient BC specific survival. There 
remained significant differences with respect to positive c-MYC expression in the survival of 
patients in both Stage I (p=0.016) and II (p=0.010) (Figure 1C-D) but not Stage III (p=0.458) 
disease (data not shown). 
Moreover, there was a significant association between positive c-MYC protein expression 
and shorter distant metastases free survival in unselected breast tumours (p=0.017, Figure 1E) 
which was maintained in luminal A tumours (p=0.013, Figure 1F) but not in basal-like or 
HER2+ tumours (Figures 1G-H). c-MYC expression was associated with the development of 
bone metastases (p=0.019) in unselected tumours, while in the Luminal A population positive 
c-MYC expression was associated with liver metastases (p=0.039).  
In terms of adjuvant treatment, positive c-MYC expression significantly predicted a shorter 
DM free survival in luminal A tumours treated with endocrine therapy (p=0.002, Figure 1I) 
but not in patients who did not receive adjuvant therapy (Figure 1J).  
Additionally, the prediction of a shorter DM free survival in luminal A tumours treated with 
adjuvant endocrine therapy was observed in LN+ tumours (Figure 1K, p=0.012) but not LN- 
tumours (Figure 1L). In multivariate Cox Regression analysis, c-MYC remained an 
independent predictor of a shorter DM free survival in luminal A LN+ tumours treated with 
endocrine therapy (p=0.013, Table 3).  
3.5 Regulation of genes by MYC in biological subtypes 
!  13
Top pair-wise interactions for genes probe markers associated with MYC expression in ER 
positive and ER negative tumours showed several different hubs indicated to be highly 
influential or regulated in the MYC system.  
In ER positive disease, MYC mRNA was significantly associated with genes implicated in 
translational (initiation elongation and termination) together with cellular protein metabolism 
(Table 4). In addition, the high expression of MYC was associated with the down regulation 
of several key hubs including genes for Translocase Of Outer Mitochondrial Membrane 40 
Homolog (Yeast)-Like (TOMM40L) and Pre-B-Cell Leukaemia Homeobox Interacting 
Protein 1 (PBXIP1; Figure 2A).   
In contrast, within ER negative disease, MYC mRNA was significantly associated with genes 
associated with glucose homeostasis, glucose metabolism and glucose transport (Table 4).  
MYC was also associated with upregulation by several genes of which Calcium Channel 
Flower Domain Containing 1 (CACFD1) and Proline Dehydrogenase (Oxidase) 1 (PRODH) 
were centralised hubs (Figure 2B). 
4. Discussion 
Studies that address the prognostic significance of c-MYC protein and its influence on the 
response of therapeutic regimens are limited. In the current study, a large number of breast 
tumours were investigated for MYC mRNA and c-MYC protein expression in order to better 
understand the potential roles of this complex protein in BC. 
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There is a wealth of studies that describe MYC amplifications in BC, although the frequency 
of this amplification is highly variable(Adem et al., 2004, Al-Kuraya et al., 2004, Borg et al., 
1992, Robanus-Maandag et al., 2003, Rodriguez-Pinilla et al., 2007, Rummukainen et al., 
2001, Schlotter et al., 2003, Cancer Genome Atlas, 2012). In this study, the expression of 
MYC was observed in 13.2% of breast tumours is however in line with the large meta-
analysis study showing amplification of MYC  in 15.7% of BC(Deming et al., 2000). 
Additionally, MYC expression was similarly associated with higher tumour grade and poor 
patient survival as observed with MYC amplification(Deming et al., 2000). 
The expression of c-MYC protein was observed in 52.2% of invasive BC, which is within the 
range of other immunohistochemical studies (45-94%)(Naidu et al., 2002, Spandidos et al., 
1989, Spaventi et al., 1994). Although in this study the correlation between measurements of 
mRNA expression and those for protein expression was not perfect, MYC gene amplification, 
has been reported to be significantly associated with overexpression of its mRNA and 
protein. Moreover, some authorities have reported MYC gene amplification in 15% of breast 
tumours, whereas mRNA level was overexpressed in 22% to 35% of tumors. However, up to 
40% of breast tumors showed MYC protein overexpression. These figures indicate that MYC 
overexpression could be attributed to different mechanisms including gene amplification, 
transcriptional regulation and mRNA and protein stabilization (reviewed in (Xu et al., 2010)). 
Therefore, variation between gene and protein expression is likely. When tumours were 
stratified according to histological type, medullary-like tumours showed the highest 
frequency of c-MYC expression while most of the lobular carcinoma showed low c-MYC 
expression. This is consistent with previous studies that observed rare MYC amplification/c-
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MYC protein overexpression in lobular carcinomas, whereas it is more frequent in non-
lobular breast carcinomas(Janocko et al., 2001, Spaventi et al., 1994).  
In this study, high expression of MYC was associated with higher tumour grade and the 
basal-like phenotype. This is in agreement with previous clinicopathological studies (Cancer 
Genome Atlas, 2012, Deming et al., 2000, Liao and Dickson, 2000, Rodriguez-Pinilla et al., 
2007, Rummukainen et al., 2001, Naidu et al., 2002, Schmitt and Reis-Filho, 2002, 
Shanmugham et al., 2004). However, there was a lack of significant relation with tumour size 
or hormone receptor status; absence of these relationships have been demonstrated in 
previous studies [30, 32]. These findings are not surprising in view of the multifunctional 
nature of MYC oncogene, with pivotal roles in proliferation, differentiation and cell death. 
In the whole cohort, high MYC and c-MYC expression was associated with poor patient 
survival. Additionally c-MYC predicted a shorter metastatic free survival and this 
significance was maintained in multivariate analysis independently of tumour grade, nodal 
stage and size. Moreover, the relation between c-MYC and the development of resistance to 
antiestrogen treatment has been addressed in many studies(Planas-Silva et al., 2007, McNeil 
et al., 2006, Musgrove et al., 2008, Santos et al., 1988, Venditti et al., 2002) and is in 
agreement with our observations in relation between high c-MYC expression and shorter DM 
free survival in those patients who received hormonal treatment and was an independent 
prognostic indicator for such group. Unlike Roux-Dosseto et al, there was no significant 
association between tumour relapse and c-MYC expression in lymph node negative 
patients(Roux-Dosseto et al., 1992). c-MYC protein may affect the response to chemotherapy 
probably through DNA damage response regulation(Aulmann et al., 2006, Berns et al., 
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1992a, Berns et al., 1992b, Gewirtz et al., 1998, Nass and Dickson, 1997) although in the 
current study, we found no evidence for this. Interestingly, MYC amplification in colon 
carcinoma predicts better response to 5-FU adjuvant chemotherapy (disease-free and cancer 
specific survivals have been improved by 30 %)(Arango et al., 2001, Barratt et al., 2002), but 
only in p53 wild-type tumours. Although this type of study in BC has not been published yet, 
Rakha et al. described improvement of the poor prognosis of basal subtype of triple negative 
BC by treatment with chemotherapy(Rakha et al., 2007). These types of tumours often have 
amplified EGFR gene(Reis-Filho et al., 2005) and according to the described MYC co-
amplification in BC(Al-Kuraya et al., 2004, Miura et al., 2008), and the association between 
c-MYC expression and basal-like BC, we may hypothesise the possibility that c-MYC 
overexpression may contribute to favourable response to chemotherapy, specially whose 
which contain 5-FU. Suppression of C-MYC transcription in breast cancer cells after 5-FU 
treatment supports the direct effect of 5-FU on the oncogene activity, probably mediated by 
upstream signalling inhibition(Hernandez-Vargas et al., 2006). 
We observed that c-MYC expression in luminal A tumours was associated with negative/low 
PI-3 kinase expression. Indeed, using a mouse BC model, PIK3CA-driven recurrent tumours 
with MYC amplification can lead to the inactivation of PIK3CA and remain independent of 
the PI-3 kinase pathway resulting in tumours developing resistance to PI-3 kinase pathway-
specific targeted therapies(Liu et al., 2011). This could suggest that in luminal A tumours, 
compared with other biological subtypes of BC, are more susceptible to PI-3 kinase inhibitor 
resistance. Within luminal A tumours, high c-MYC expression was also associated with an 
increase in cell cycle activity indicated by high expression of Cyclin B1 and Ki67. Regulation 
of cyclin B1 is essential for the initiation of mitosis as it regulates the G2-M transition of the 
!  17
cell cycle. MYC regulates the CCNB1 gene promoter and the high expression of Cyclin B1 
seen in the Luminal A tumours, which has previously been associated with poor prognosis of 
hormone receptor positive BC(Agarwal et al., 2009, Hu et al., 2006), is most likely as a 
consequence of this regulation. 
In basal-like tumours, c-MYC expression was associated with Cyclin E and the cyclin-
dependent kinase inhibitor p16. p16 has previously been associated ER negative BC and poor 
patient outcome particularly those treated with adjuvant chemotherapy(Dublin et al., 1998, 
Han et al., 2001, Nemtsova et al., 2007). Both cyclin-E and p16 are inextricably linked with 
the G1-S phase transition of the cell cycle. c-MYC is an upstream activator of cyclin-E/
CDK2 activity and promotes cell cycle progression from G1 to S phase independent of the 
Rb pathway and can compensate for low cyclin D/cdk4 kinase activity(Alevizopoulos et al., 
1997, Gray-Bablin et al., 1996), whereas p16 arrests this transcriptional activity at the G1 
phase. Rb is thought to promote an aggressive form of triple negative BC with MYC 
overexpression although in the current study we found no evidence that RB was associated 
with c-MYC expression in any BC biological subtype(Knudsen et al., 2015). The p16 protein 
has a very long half-life(Sherr, 1996) and therefore accumulates in the cells with increasing 
number of cell cycles. This might partly explain high p16 expression in tumours with high 
growth fraction. 
Whilst co-amplification of MYC and HER2 has previously been associated with very poor 
patient outcome in BC by promoting a stem-like phenotype(Nair et al., 2014), we found no 
evidence to suggest this particularly as there was a negative relationship between MYC 
expression and HER2 status. We did however observe that in HER2+ tumours, there was a 
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significant relationship between c-MYC protein and high cell proliferation, as determined by 
Ki67, suggesting that co-expression is linked with more aggressive tumours. Conversely, 
there was also high correlation with the co-expression of c-MYC and ATM in HER2+ 
suggesting that whilst these tumours are highly proliferative, they are also undergoing higher 
levels of cell cycle arrest, DNA repair or apoptosis by MYC activating ATM-dependent 
checkpoint responses(Guerra et al., 2010).  
The mechanisms of MYC were further explored in ER positive and ER negative tumours 
using ANN analysis of the METABRIC data. Here, we show that MYC is potentially driving 
glucose metabolism in ER negative, but not ER positive, tumours providing necessary energy 
required for cell proliferation (the Warburg effect); a key feature of these poor prognostic 
tumours. It is well-documented that c-MYC regulates glucose metabolism and glutamine 
uptake and contributes to the metabolic pre-programming required for cancer cells to adapt to 
the tumour microenvironment (for reviews see (Li and Simon, 2013, Wahlstrom and Arsenian 
Henriksson, 2015)). Our data confirms previous studies in triple-negative breast tumours 
where those with MYC gene copy gain have increased glucose uptake(Palaskas et al., 2011) 
expression of thioredoxin-interacting protein (TXNIP) is down-regulated driving the 
activation of glucose metabolism(Shen et al., 2015). A mechanistic association between MYC 
and glucose metabolism in endocrine resistance in BC has also recently been 
described(Shajahan-Haq et al., 2014). 
In ER positive tumours, MYC was associated with translational function particularly the 
family of ribosomal subunit proteins (RPLs) and eukaryotic translation initiation factors 
(eIFs). Increases in rRNA synthesis, ribosomal biogenesis and translational initiation/
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elongation are common cancer features which can be driven by MYC (for review see 
(Ruggero, 2009)) and we show that enhanced ribosome assembly and transcriptional activity 
is a probable feature of luminal BC.  
5. Conclusions 
Whilst MYC is multifunctional, it is apparent that different biological pathways are 
predominant in the separate molecular subtypes of breast cancer. The diverse mechanisms of 
c-MYC function as potential therapeutic targets, particularly in breast cancer subtypes 
therefore warrants further investigation.  
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Figure 1. MYC and breast cancer patient outcome: A) MYC (BCSS), B) c-MYC (BCSS), C) c-
MYC in Stage I disease (BCSS), D) c-MYC in Stage II disease (BCSS), E) c-MYC (DMFS), F) c-
MYC in luminal A tumours (DMFS), G) c-MYC in basal-like tumours (DMFS), H) c-MYC in 
HER2+ tumours (DMFS), I) c-MYC in luminal A tumours treated with endocrine therapy 
(DMFS), J) c-MYC in luminal A tumours with no adjuvant treatment (DMFS), K) c-MYC in 
luminal A lymph node positive patients treated with endocrine treatment, L) c-MYC in 
luminal A Lymph node negative patients treated with endocrine treatment. BCSS= breast 
cancer specific survival, DMFS=distant metastases free survival. Green=positive; 
blue=negative. 
Figure 2. Top pair-wise interactions for genes associated with MYC expression show hubs 
that are indicated to be highly influential or regulated in the MYC system in A) ER positive 
and B) ER negative disease. Each gene probe is represented by a node and the interaction 
weight between them as an edge, the width being defined by the magnitude of the 
weight. Interactions are directed from a source gene to a target gene as indicated by 
arrows. Red interactions indicate an excitatory interaction and blue indicates an inhibitory 
interaction. Red node gradient represents a positive fold change and green node gradient 
represents a negative fold change in the high MYC class.   
Supplementary Figure 1 
Supplemtenary Figure 2. c-MYC expression A) validation of antibody using Western Blot in 
MDA-MB-468 breast cancer cell line Lane 1: β-actin 2: Size Ladder 3: c-MYC, nuclear 
expression in invasive breast cancer, B) cytoplasmic expression expression in invasive 
breast cancer. Original magnification x400.  
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